XBIO
Xenetic Biosciences Inc
NASDAQ: XBIO · HEALTHCARE · BIOTECHNOLOGY
$3.03
+1.00% today
Updated 2026-04-30
Market cap
$6.87M
P/E ratio
—
P/S ratio
2.31x
EPS (TTM)
$-1.58
Dividend yield
—
52W range
$2 – $14
Volume
0.0M
Xenetic Biosciences Inc (XBIO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-90.10%
Operating margin
-81.30%
ROE
-40.00%
ROA
-23.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $293603.00 | $-6.33M | 84.73% | -2,160.83% | -2,155.41% |
| 2013 | $1.00M | $-8.58M | 99.16% | -861.35% | -857.92% |
| 2014 | $0.00 | $-14.31M | — | — | — |
| 2015 | $0.00 | $-12.51M | — | — | — |
| 2016 | $3.00M | $-54.21M | 98.79% | -1,581.02% | -1,806.87% |
| 2017 | $7.58M | $-3.60M | 97.94% | -47.05% | -47.40% |
| 2018 | $0.00 | $-7.30M | — | — | — |
| 2019 | $17066.00 | $-12.78M | 100.00% | -75,511.71% | -74,856.59% |
| 2020 | $436942.00 | $-10.89M | 100.00% | -3,189.82% | -2,493.11% |
| 2021 | $1.16M | $-5.65M | 100.00% | -495.12% | -486.36% |
| 2022 | $1.71M | $-6.55M | 100.00% | -393.57% | -383.87% |
| 2023 | $2.54M | $-4.13M | 100.00% | -177.79% | -162.78% |
| 2024 | $2.50M | $-3.96M | 100.00% | -168.16% | -158.39% |
| 2025 | $2.98M | $-2.68M | 100.00% | -95.23% | -90.07% |